Completed PHASE1 INTERVENTIONAL 2-arm NCT04798313

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults (MW031)

A Single Center, Randomized, Double-blind , Single-dose, and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of MW031 and Prolia® in Healthy Adults

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions Osteoporosis, Postmenopausal

Interventions MW031 Prolia®

Updated 3 times since 2021 Last updated: Mar 12, 2021 Started: Jun 2, 2020 Primary completion: Dec 7, 2020 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04798313, this PHASE1 trial focuses on Osteoporosis, Postmenopausal and remains completed. Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd., it has been updated 3 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2021 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mabwell (Shanghai) Bioscience Co., Ltd.

Data source: Mabwell (Shanghai) Bioscience Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zibo, China